Create a narrative

CureVac Community

NasdaqGM:CVAC Community

1 Narratives written by author
0 Comments on narratives written by author
22 Fair Values set on narratives written by author

AN

AnalystConsensusTarget

AnalystConsensusTarget

Consensus Narrative from 4 Analysts

GSK Milestones And Tech Focus Will Shape Oncology Amid Risks

Key Takeaways Strategic focus on innovation and R&D in oncology and infectious diseases positions CureVac for potential high-growth opportunities and revenue enhancement. Strong intellectual property, promising GSK licensing agreements, and a solid cash position bolster competitive edge and future revenue prospects.

US$5.35

FV

1.0% overvalued

-33.07%

Revenue growth p.a.

0

0

9

28 days ago